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a meta-analysis of GWAS with > 2,500,000 imputed SNPs in Caucasian
women from four population-based cohorts: three cohorts from the Rotter-
dam Study (RS-I, RS-II, and RS-III) and the Erasmus Rucphen Family (ERF)
Study. Controls using analgesics were excluded. In total approximately 680
cases and 4180 controls were included in the meta-analysis. The program
METAL was used to perform the meta-analysis using an additive model. The
genomic control method was used to correct for any residual population
stratiﬁcation or relatedness not accounted for by the four most important
PCs (all lambda’s < 1.1).
Results: The average prevalence of CWP in the four studies was 15%. The
most signiﬁcant signal of the meta-analysis was at 4p15.3, in intron 1 of
Prominin 1 (PROM1), which reached borderline genome wide signiﬁcance
(p=5.5×10-8). The effect allele T (minor allele frequency = 6%) of the
most signiﬁcant SNP gives a consistent higher risk for CWP in all four
cohorts examined (meta-analysis OR per T-allele: 1.74, 95% CI: 1.43-2.14,
p=5.5×10-8). As observed from RS-I data, the effect allele also gives a
higher risk for joint speciﬁc pain in hip (p = 0.024, OR: 1.34, 95% CI:
1.03-1.71), hand (p=0.021, OR: 1.31, 95% CI: 1.04-1.65), and low back and
neck (p=0.001, OR: 1.43, 95% CI: 1.16-1.76). The PROM1 gene encodes a
pentaspan transmembrane glycoprotein, for which no link with CWP has
been established yet.
Conclusions: This large GWAS meta-analysis on CWP shows a strongly
suggestive association for CWP in women at chr4p15.3, just escap-
ing genome-wide signiﬁcance. Therefore, replication in other cohorts is
needed, which might unveil further loci for CWP.
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Purpose: To clarify the role of common genetic variation in the Interleukin-
1β (IL1B) and Interleukin-1R antagonist (IL1RN) genes on risk of prevalence
of knee and hip osteoarthritis (OA) and severity of knee OA by means of
large-scale meta-analyses.
Methods: We searched PubMed for articles assessing the role of IL1B and
IL1RN polymorphisms and haplotypes on the risk of hip and/or knee OA.
Novel data was included from 8 additional studies. A meta-analysis was
performed using ﬁxed- and random-effects models, including all available
data with allele/genotype counts, with a total of 3676 hip OA and 5128
knee OA cases, and 6559 and 9132 controls respectively. The role of ILRN
haplotypes on radiographic severity of knee OA, previously reported, was
tested in 1918 cases with Kellgren-Lawrence (K/L) 1 or 2 compared to 199
cases with K/L 3 or 4.
Results: The meta-analysis showed no evidence of association between
common genetic variation in the IL1B or IL1RN genes and risk of hip
OA or knee OA (P>0.05 for rs16944, rs1143634, rs419598 and haplotype
C-G-C (rs1143634, rs16944 and rs419598) previously implicated in risk of
hip OA). The C-T-A haplotype formed by rs419598, rs315952 and rs9005,
previously implicated in radiographic severity of knee OA, was associated
with reduced severity of knee OA (OR=0.71 95%CI 0.56-0.91; P=0.006,
I2=74%), but did not achieve statistical signiﬁcance in a random effects
model (OR=0.61 95%CI 0.35-1.06 P=0.08).
Conclusions: Common genetic variation in the Interleukin-1 region is not
associated with prevalence of hip or knee OA but may be associated with
severity of knee OA.
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Purpose: Osteoarthritis (OA), the most common form of arthritis, is a mul-
tifactorial disease thought to be caused by complex interplay between envi-
ronmental and genetic factors. The genetic architecture of OA has not been
characterised yet; as with many common complex traits it appears to be
of a highly polygenic nature with multiple risk loci conferring small effects,
detection of which necessitates studies in sets of large sample sizes. In order
to enable a well-powered genome-wide association study (GWAS) for OA,
we have formed the arcOGEN Consortium, a UK-wide collaboration aiming
to carry out a genome-wide scan of 8,000 OA cases in a 2-stage GWAS.
Methods: We have completed stage 1 GWAS in 3,177 knee and/or hip OA
cases, genotyped on the Illumina Human610 chip and have compared their
genotypes against 4,894 publicly available population-based UK controls
from the Wellcome Trust Case Control Consortium 2 (WTCCC2) study,
genotyped on the Illumina 1.2M platform.
Results: Of the 514,898 single nucleotide polymorphisms (SNPs) that
passed our quality control, 90 SNPs reached p values < 0.0001 (as op-
posed to 51 expected under the null hypothesis of no association). We
took forward 102 independent (r2<0.4) SNPs with p<0.0001 to in silico
replication in three further OA GWAS (from the deCODE, Framingham and
Rotterdam studies) and a subset of 52 SNPs in a UK-based GWAS (Twins
UK) comprising a total of 41,075 individuals. Based on meta-analysis results
across the arcOGEN and in silico replication datasets we prioritised 36 SNPs
for de novo replication in a further set of 6,255 OA cases and 8,289 controls
of European ancestry (from Spain, Greece, USA and the Netherlands). None
of the followed-up signals reached genome-wide signiﬁcance (p<5×10-8),
but this could be due to low power caused by limited sample size, small
effect sizes and phenotype heterogeneity. In the knee and/or hip OA
meta-analysis across the discovery and replication sets, the strongest signal
was observed for rs2277831, which lies within the MICAL3 gene (odds
ratio for the G allele (OR) 1.07 [1.04-1.11], p=2.85×10-5). We also examined
